Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celularity IncCELU · Entity 7145 | Director | January 12, 2026 | January 15, 2026 |
| DPCM Capital, Inc.XPOA · Entity 124742 | Director | August 05, 2022 | August 09, 2022 |
| Nogin, Inc.SWAG · Entity 111866 | Director | July 28, 2021 | July 28, 2021 |
| Software Acquisition Group Inc. IISAIIU · Entity 140697 | Director | September 14, 2020 | September 14, 2020 |
| Vaxxinity, Inc.VAXX · Entity 91688 | Director | June 20, 2023 | June 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celularity Inc
Report date January 12, 2026 · Filed January 15, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 394,150 |
Reported balance
After 2026-01-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 20,385 · Balance 394,150 F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. F2: Includes 20,385 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
F2: Includes 20,385 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
DPCM Capital, Inc.
Report date August 05, 2022 · Filed August 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-05 · Conversion · Acquired 45,000 · Balance 45,000 F1: As describd in the DPCM Capital, Inc.'s registration statement on Form S-1 (File No. 333-249274) under the heading "Description of Securities," the Class B Common Stock of the issuer automatically converts into Class A Common Stock of the issuer ("Class A Common Stock") at the time of the issuer's initial business combination or earlier at the option of the holders thereof, on a one-for-one basis, subject to certain adjustments described therein, and have no expiration date. F2: (Continued from Footnote 1) On August 5, 2022, the issuer consummated its initial business combination (the "Business Combination") with D-Wave Quantum, Inc. ("Newco"), a Delaware corporation. In connection with the Business Combination, each share of Class B Common Stock converted into Class A Common Stock. Row 2 · 2022-08-05 · Other · Disposed 45,000 · Balance 0 F3: In connection with the Business Combination, the Reporting Person exchanged its shares of Class A Common Stock for 45,000 fully paid and non-assessable shares of common stock, par value U.S. $0.0001 per share of Newco. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-08-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-05 · Conversion · Disposed 45,000 · Balance 0 F1: As describd in the DPCM Capital, Inc.'s registration statement on Form S-1 (File No. 333-249274) under the heading "Description of Securities," the Class B Common Stock of the issuer automatically converts into Class A Common Stock of the issuer ("Class A Common Stock") at the time of the issuer's initial business combination or earlier at the option of the holders thereof, on a one-for-one basis, subject to certain adjustments described therein, and have no expiration date. F2: (Continued from Footnote 1) On August 5, 2022, the issuer consummated its initial business combination (the "Business Combination") with D-Wave Quantum, Inc. ("Newco"), a Delaware corporation. In connection with the Business Combination, each share of Class B Common Stock converted into Class A Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: As describd in the DPCM Capital, Inc.'s registration statement on Form S-1 (File No. 333-249274) under the heading "Description of Securities," the Class B Common Stock of the issuer automatically converts into Class A Common Stock of the issuer ("Class A Common Stock") at the time of the issuer's initial business combination or earlier at the option of the holders thereof, on a one-for-one basis, subject to certain adjustments described therein, and have no expiration date.
F2: (Continued from Footnote 1) On August 5, 2022, the issuer consummated its initial business combination (the "Business Combination") with D-Wave Quantum, Inc. ("Newco"), a Delaware corporation. In connection with the Business Combination, each share of Class B Common Stock converted into Class A Common Stock.
F3: In connection with the Business Combination, the Reporting Person exchanged its shares of Class A Common Stock for 45,000 fully paid and non-assessable shares of common stock, par value U.S. $0.0001 per share of Newco.
Nogin, Inc.
Report date July 28, 2021 · Filed July 28, 2021
This filing explicitly reported no securities owned.
Software Acquisition Group Inc. II
Report date September 14, 2020 · Filed September 14, 2020
This filing explicitly reported no securities owned.
Vaxxinity, Inc.
Report date June 20, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 | Direct | 132,352 |
Reported balance
After 2023-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-20 · Grant · Acquired 132,352 · Balance 132,352 F1: These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation. F2: These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the Issuer through the vesting date. F3: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation.
F2: These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the Issuer through the vesting date.
F3: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CuriosityStream Inc.
Report date November 18, 2020 · Filed November 20, 2020
Section 16 reporting ended · disclosed 2020-11-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Sponsor | 0 |
Reported balance
After 2020-11-18 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-11-18 · Other · Disposed 3,737,500 · Balance 0 F1: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer. F2: Pro rata distribution of Common Stock from the Sponsor, of which the reporting person is a member. |
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2020-11-18 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-11-18 · Other · Acquired 20,000 · Balance 20,000 F1: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer. F2: Pro rata distribution of Common Stock from the Sponsor, of which the reporting person is a member. |
Filing footnotes · ownership attribution and instrument terms
F1: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer.
F2: Pro rata distribution of Common Stock from the Sponsor, of which the reporting person is a member.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 14, 2026 20:51 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 20,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-002298 · ownership.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,150 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 20,385 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 16:15 UTC Amendment | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 20,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-002425 · ownership.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,150 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. F2 · balance_after: Includes 20,385 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 16:30 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Options · Derivative | 156,250 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001493152-25-029614 · ownership.xml · derivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 518,774 Underlying: Class A Common Stock · 156,250 shares Expires 2035-12-29 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 16:30 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-029614 · ownership.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,765 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 125,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 16:30 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 67,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-028778 · ownership.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,765 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs vested on December 19, 2025. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:15 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 47,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-024630 · ownership.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,765 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the date of grant. Read SEC document |
| December 19, 2024 Filed Jan 6, 2025 16:54 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 84,746 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001493152-25-001035 · ownership.xml · derivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,524 Underlying: Class A Common Stock · 84,746 shares Expires 2034-12-19 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 19, 2024 Filed Jan 6, 2025 16:54 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 67,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-001035 · ownership.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,374,482 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 67,416 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 19, 2024 Filed Mar 3, 2025 16:30 UTC Amendment | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 84,746 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001493152-25-008871 · ownership.xml · derivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,459 Underlying: Class A Common Stock · 84,746 shares Expires 2034-12-19 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 19, 2024 Filed Mar 3, 2025 16:30 UTC Amendment | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 67,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-008871 · ownership.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,723 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 67,416 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| June 20, 2023 Filed Jun 26, 2023 18:32 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | GrantStock option (right to buy) · Derivative | 132,352 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001437749-23-018535 · rdgdoc.xml · derivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,352 Underlying: Class A common stock · 132,352 shares Expires not disclosed F1 · date: These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation. F2 · derivative.exercise_date: These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the Issuer through the vesting date. F3 · derivative.expiration_date: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:48 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 277,778 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0000899243-23-015863 · doc4.xml · derivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,778 Underlying: Class A Common Stock · 277,778 shares Expires 2033-06-14 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:48 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 199,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015863 · doc4.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,307,066 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 199,921 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| April 26, 2023 Filed May 2, 2023 10:46 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionStock option (right to buy) · Derivative | 46,500 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001437749-23-012008 · rdgdoc.xml · derivative · entry 6 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,642 Underlying: Class A common stock · 46,500 shares Expires 2031-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are subject to a four-year vesting schedule, beginning on June 2, 2020, vesting in equal installments each month during the vesting period. Read SEC document |
| April 26, 2023 Filed May 2, 2023 10:46 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionStock option (right to buy) · Derivative | 429,037 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001437749-23-012008 · rdgdoc.xml · derivative · entry 5 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,009 Underlying: Class A common stock · 429,037 shares Expires 2031-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are subject to a four-year vesting schedule, with 25% having vested on December 30, 2020 and the remainder vesting in thirty-six equal installments each month during the remainder of the vesting period Read SEC document |
| April 26, 2023 Filed May 2, 2023 10:46 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionClass A common stock | 46,500 | $1.21 | $56,265.00 |
DisclosureSEC source: 0001437749-23-012008 · rdgdoc.xml · nonDerivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 906,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2023 Filed May 2, 2023 10:46 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionClass A common stock | 429,037 | $0.57 | $244,551.09 |
DisclosureSEC source: 0001437749-23-012008 · rdgdoc.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 859,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 19:24 UTC | Celularity Inc CELU · Entity 7145 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,071,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000899243-23-005063 · doc4.xml · derivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,660,136 Underlying: Class A Common Stock · 1,071,000 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 19:24 UTC | Celularity Inc CELU · Entity 7145 | Exercise / conversionClass A Common Stock | 1,071,000 | $0.28 | $299,880.00 |
DisclosureSEC source: 0000899243-23-005063 · doc4.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 36,145 shares underlying restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs vest and become exercisable on the earlier of the one-year anniversary of the date of grant, July 13, 2022, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:31 UTC | DPCM Capital, Inc. XPOA · Entity 124742 | ConversionClass B Common Stock · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-028097 · doc4.xml · derivative · entry 3 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 45,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: As describd in the DPCM Capital, Inc.'s registration statement on Form S-1 (File No. 333-249274) under the heading "Description of Securities," the Class B Common Stock of the issuer automatically converts into Class A Common Stock of the issuer ("Class A Common Stock") at the time of the issuer's initial business combination or earlier at the option of the holders thereof, on a one-for-one basis, subject to certain adjustments described therein, and have no expiration date. F2 · derivative.exercise_price: (Continued from Footnote 1) On August 5, 2022, the issuer consummated its initial business combination (the "Business Combination") with D-Wave Quantum, Inc. ("Newco"), a Delaware corporation. In connection with the Business Combination, each share of Class B Common Stock converted into Class A Common Stock. F1 · derivative.exercise_date: As describd in the DPCM Capital, Inc.'s registration statement on Form S-1 (File No. 333-249274) under the heading "Description of Securities," the Class B Common Stock of the issuer automatically converts into Class A Common Stock of the issuer ("Class A Common Stock") at the time of the issuer's initial business combination or earlier at the option of the holders thereof, on a one-for-one basis, subject to certain adjustments described therein, and have no expiration date. F2 · derivative.exercise_date: (Continued from Footnote 1) On August 5, 2022, the issuer consummated its initial business combination (the "Business Combination") with D-Wave Quantum, Inc. ("Newco"), a Delaware corporation. In connection with the Business Combination, each share of Class B Common Stock converted into Class A Common Stock. F1 · derivative.expiration_date: As describd in the DPCM Capital, Inc.'s registration statement on Form S-1 (File No. 333-249274) under the heading "Description of Securities," the Class B Common Stock of the issuer automatically converts into Class A Common Stock of the issuer ("Class A Common Stock") at the time of the issuer's initial business combination or earlier at the option of the holders thereof, on a one-for-one basis, subject to certain adjustments described therein, and have no expiration date. F2 · derivative.expiration_date: (Continued from Footnote 1) On August 5, 2022, the issuer consummated its initial business combination (the "Business Combination") with D-Wave Quantum, Inc. ("Newco"), a Delaware corporation. In connection with the Business Combination, each share of Class B Common Stock converted into Class A Common Stock. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:31 UTC | DPCM Capital, Inc. XPOA · Entity 124742 | OtherClass A Common Stock | 45,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-028097 · doc4.xml · nonDerivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: In connection with the Business Combination, the Reporting Person exchanged its shares of Class A Common Stock for 45,000 fully paid and non-assessable shares of common stock, par value U.S. $0.0001 per share of Newco. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:31 UTC | DPCM Capital, Inc. XPOA · Entity 124742 | ConversionClass A Common Stock | 45,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-028097 · doc4.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As describd in the DPCM Capital, Inc.'s registration statement on Form S-1 (File No. 333-249274) under the heading "Description of Securities," the Class B Common Stock of the issuer automatically converts into Class A Common Stock of the issuer ("Class A Common Stock") at the time of the issuer's initial business combination or earlier at the option of the holders thereof, on a one-for-one basis, subject to certain adjustments described therein, and have no expiration date. F2 · price: (Continued from Footnote 1) On August 5, 2022, the issuer consummated its initial business combination (the "Business Combination") with D-Wave Quantum, Inc. ("Newco"), a Delaware corporation. In connection with the Business Combination, each share of Class B Common Stock converted into Class A Common Stock. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 21:21 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 54,152 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0000899243-22-026206 · doc4.xml · derivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,152 Underlying: Class A Common Stock · 54,152 shares Expires 2032-07-13 F2 · derivative.exercise_date: This option is granted under the Issuer's 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, July 13, 2022, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 21:21 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 36,145 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-026206 · doc4.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,145 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs is shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, July 13, 2022, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 19:58 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | GrantStock option (right to buy) · Derivative | 129,187 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001437749-22-015780 · rdgdoc.xml · derivative · entry 4 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,187 Underlying: Class A common stock · 129,187 shares Expires not disclosed F1 · date: These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation. F2 · derivative.exercise_date: These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the issuer through the vesting date. F3 · derivative.expiration_date: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 18:39 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionStock Option (right to buy) · Derivative | 652,764 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0000899243-22-003306 · doc4.xml · derivative · entry 4 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,191 Underlying: Class A common stock · 652,764 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Reporting Person held 815,955 of these stock options set to expire on 1/26/2022 at the time of the transaction. 80% of the stock options vested upon closing of the initial public offering, and the remaining 20% are expected to expire before meeting vesting conditions. Previously, these stock options were incorrectly reported as having an expiration date of the earlier of one year following vesting and 8/3/2031. F3 · derivative.expiration_date: The Reporting Person held 815,955 of these stock options set to expire on 1/26/2022 at the time of the transaction. 80% of the stock options vested upon closing of the initial public offering, and the remaining 20% are expected to expire before meeting vesting conditions. Previously, these stock options were incorrectly reported as having an expiration date of the earlier of one year following vesting and 8/3/2031. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 18:39 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionClass A common stock | 652,764 | $4.12 | $2,688,865.47 |
DisclosureSEC source: 0000899243-22-003306 · doc4.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2022 Filed Jun 23, 2022 19:49 UTC Amendment | Vaxxinity, Inc. VAXX · Entity 91688 | Tax withholdingClass A common stock | 312,659 | $8.60 | $2,688,867.40 |
DisclosureSEC source: 0001437749-22-015775 · rdgdoc.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,604 F1 · shares: The Reporting Person unintentionally omitted this transaction from the Form 4 filed on January 26, 2022. These disposed shares were cancelled as part of a cashless exercise of stock options. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 18:00 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | OtherClass A common stock | 76,923 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045293 · doc4.xml · nonDerivative · entry 3 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,923 F3 · acquired: Represents a pro-rata in kind distribution of the Class A common stock held by Bald Eagle IV LLC to one of its members. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 18:00 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | OtherClass A common stock | 76,923 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045293 · doc4.xml · nonDerivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Bald Eagle IV LLC Disclosed balance after: 0 F2 · ownership.nature: Held by Bald Eagle IV LLC. The Reporting Person is a member of Bald Eagle IV LLC. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of all securities held by Bald Eagle IV LLC in which the Reporting Person has no pecuniary interest. Read SEC document |
| November 18, 2021 Filed Jun 23, 2022 19:47 UTC Amendment | Vaxxinity, Inc. VAXX · Entity 91688 | SaleClass A common stock | 248 | $13.00 | $3,224.00 |
DisclosureSEC source: 0001437749-22-015774 · rdgdoc.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,499 F1 · shares: In the Form 4 filed on November 18, 2021, the Reporting Person omitted this sale of stock to cover fees in connection with the previously reported transaction. Read SEC document |
| November 15, 2021 Filed Nov 15, 2021 18:53 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | ConversionSeries A preferred stock · Derivative | 21,511 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-044652 · doc4.xml · derivative · entry 4 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by spouse Disclosed balance after: 0 Underlying: Class A common stock · 13,824 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F1 · shares: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F1 · price: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F1 · derivative.exercise_date: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F1 · derivative.expiration_date: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F1 · derivative.underlying_shares: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F2 · ownership.nature: These securities are held by Kristin Diamandis, the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Kristin Diamandis in which the Reporting Person has no pecuniary interest. Read SEC document |
| November 15, 2021 Filed Nov 15, 2021 18:53 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | PurchaseClass A common stock | 76,923 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044652 · doc4.xml · nonDerivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Bald Eagle IV LLC Disclosed balance after: 76,923 F3 · shares: The Reporting Person beneficially owns 76,923 shares of Class A common stock purchased by Bald Eagle IV LLC. F4 · ownership.nature: Held by Bald Eagle IV LLC. The Reporting Person is a member of Bald Eagle IV LLC. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of all securities held by Bald Eagle IV LLC in which the Reporting Person has no pecuniary interest. Read SEC document |
| November 15, 2021 Filed Nov 15, 2021 18:53 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | ConversionClass A common stock | 271,655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-044652 · doc4.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by spouse Disclosed balance after: 271,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F1 · price: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F2 · ownership.nature: These securities are held by Kristin Diamandis, the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Kristin Diamandis in which the Reporting Person has no pecuniary interest. Read SEC document |
| November 15, 2021 Filed Jun 23, 2022 19:44 UTC Amendment | Vaxxinity, Inc. VAXX · Entity 91688 | ConversionSeries A preferred stock · Derivative | 21,511 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-015773 · rdgdoc.xml · derivative · entry 3 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 13,824 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F1 · shares: The Reporting Person unintentionally omitted this transaction from the Form 4 filed on November 15, 2021. F2 · price: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F2 · derivative.exercise_date: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F2 · derivative.expiration_date: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. Read SEC document |
| November 15, 2021 Filed Jun 23, 2022 19:44 UTC Amendment | Vaxxinity, Inc. VAXX · Entity 91688 | ConversionClass A common stock | 13,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-015773 · rdgdoc.xml · nonDerivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by spouse Disclosed balance after: 13,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The Reporting Person incorrectly reported that 271,655 shares of Class A common stock were acquired by the Reporting Person's spouse upon the conversion of Series A preferred stock. Instead, 13,824 shares of Class A common stock were acquired by the Reporting Person's spouse upon the conversion of Series A preferred stock. F2 · price: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. F4 · ownership.nature: These securities are held by Kristin Diamandis, the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Kristin Diamandis in which the Reporting Person has no pecuniary interest. Read SEC document |
| November 15, 2021 Filed Jun 23, 2022 19:44 UTC Amendment | Vaxxinity, Inc. VAXX · Entity 91688 | ConversionClass A common stock | 13,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-015773 · rdgdoc.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person unintentionally omitted this transaction from the Form 4 filed on November 15, 2021. F2 · price: Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 18:13 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 56,053 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001213900-21-047754 · ownership.xml · derivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,053 Underlying: Class A Common Stock · 56,053 shares Expires 2031-09-09 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, September 9, 2021, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 21:24 UTC | Celularity Inc CELU · Entity 7145 | GrantDeferred Compensation Award (Right to Buy) · Derivative | 269,007 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001209191-21-047518 · doc4.xml · derivative · entry 2 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,007 Underlying: Class A Common Stock · 269,007 shares Expires 2031-07-16 F2 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc." F3 · derivative.exercise_date: This Deferred Compensation Award ("DCA") shall become exercisable solely upon the first to occur of: (i) the consummation of a change of control that is also a change in the ownership or effective control of the Issuer, or in the ownership of a substantial portion of the Issuer's assets, (ii) the Reporting Person's death or disability, or (iii) March 24, 2023, subject to the Reporting Person's continuous service with the Issuer on such date. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 21:24 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 3,731,136 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001209191-21-047518 · doc4.xml · derivative · entry 1 Diamandis Peter · CIK 0001528288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,731,136 Underlying: Class A Common Stock · 3,731,136 shares Expires 2031-07-16 F2 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc." F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 22:23 UTC | CuriosityStream Inc. CURI · Entity 6455 | OtherCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-038565 · ownership.xml · nonDerivative · entry 2 Diamandis Peter · CIK 0001528288 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer. F1 · shares: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer. F2 · shares: Pro rata distribution of Common Stock from the Sponsor, of which the reporting person is a member. F1 · price: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer. F1 · balance_after: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer. F2 · balance_after: Pro rata distribution of Common Stock from the Sponsor, of which the reporting person is a member. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 22:23 UTC | CuriosityStream Inc. CURI · Entity 6455 | OtherCommon Stock | 3,737,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-038565 · ownership.xml · nonDerivative · entry 1 Diamandis Peter · CIK 0001528288 · Former Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Sponsor Disclosed balance after: 0 F1 · kind: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer. F1 · shares: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer. F1 · price: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer. F1 · balance_after: Pro rata distribution of shares of common stock, par value $0.0001 per share ("Common Stock"), of CuriosityStream Inc. (the "Company") from Software Acquisition Holdings, LLC (the "Sponsor") to certain of its members. The shares of Common Stock distributed are subject to certain restrictions on transfer. F2 · ownership.nature: Pro rata distribution of Common Stock from the Sponsor, of which the reporting person is a member. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.